RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Conference

Gilbert, Mark R, Dignam, James, Won, Minhee et al. (2013). RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). . JOURNAL OF CLINICAL ONCOLOGY, 31(15),

International Collaboration

cited authors

  • Gilbert, Mark R; Dignam, James; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Aldape, Kenneth D; Colman, Howard; Chakravarti, Arnab; Jeraj, Robert; Armstrong, Terri S; Wefel, Jeffrey Scott; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Sulman, Erik P; Mehta, Minesh P

sustainable development goals

authors

date/time interval

  • May 31, 2013 -

publication date

  • May 20, 2013

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • IL, Chicago

Conference

  • 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

volume

  • 31

issue

  • 15